Antiinflammatory properties of PPARγ agonists following ischemia

Drug News and Perspectives

Volumn 17, Issue 4, 2004, Pages 229-236

  Sundararajan, Sophia ^a   Landreth, Gary E ^b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BETA2 INTEGRIN; CD11B ANTIGEN; CD18 ANTIGEN; CHEMOKINE RECEPTOR CCR2; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; HEME OXYGENASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; LIVER X RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE SYNTHASE; OXIDIZED LOW DENSITY LIPOPROTEIN; PADGEM PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; RETINOID X RECEPTOR; ROSIGLITAZONE; STAT PROTEIN; THROMBOXANE A2; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; ANTIINFLAMMATORY AGENT; CELL RECEPTOR; LIGAND; TRANSCRIPTION FACTOR;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; B LYMPHOCYTE; BRAIN ISCHEMIA; DIABETIC ANGIOPATHY; GLUCOSE BLOOD LEVEL; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; INSULIN SENSITIVITY; LIPID METABOLISM; MIDDLE CEREBRAL ARTERY OCCLUSION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; T LYMPHOCYTE; ARTERIOSCLEROSIS; DRUG POTENTIATION; INFLAMMATION; ISCHEMIA; PATHOLOGY;

ANTI-INFLAMMATORY AGENTS; ARTERIOSCLEROSIS; BRAIN ISCHEMIA; DIABETES MELLITUS, TYPE 2; HUMANS; INFLAMMATION; ISCHEMIA; LIGANDS; MYOCARDIAL ISCHEMIA; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 3342973839     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2004.17.4.829049     Document Type: Review

References (95)

1. del Zoppo, G. Microvascular responses to cerebral ischemia/inflammation. Ann NY Acad Sci 1997, 823: 132-47.
2. Gerszten, R., Lim, Y., Ding, H. et al. Adhesion of monocytes to vascular cell adhesion molecule-1-transduced human endothelial cells - Implications for atherogenesis. Circ. Res 1998, 82: 871-8.
3. Frangogiannis, N., Smith, C. and Entman, M. The inflammatory response in myocardial infarction. Cardiovasc Res 2002, 53: 31-47.
4. Che, X., Ye, W., Panga, L., Wu, D. and Yang, G. Monocyte chemoattractant protein-1 expressed in neurons and astrocytes during focal ischemia in mice. Brain Res 2001, 902: 171-7.
5. Chen, Y., Hallenbeck, J., Ruetzler, C., Bol, D., Thomas, K., Berman, N. and Vogel, S. Overexpression of monocyte chemoattractant protein 1 in the brain exacerbates ischemic brain injury and is associated with recruitment of inflammatory cells. J Cereb Blood Flow Metab 2003, 23: 748-55.
6. Hayashidani, S., Tsutsui, H., Shiomi, T. et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2003, 108: 2134-40.
7. Hughes, P., Allegrini, P., Rudin, M., Perry, V., Mir, A. and Wiessner, C. Monocyte chemoattractant protein-1 deficiency is protective in a murine stroke model. J Cereb Blood Flow Metab 2002, 22: 308-17.
8. Chopp, M., Jiang, C., Zhang, R., Qin, Z. and Prosak, I. Antibodies against adhesion molecules reduce apoptosis after transient middle cerebral artery occlusion in rat brain. FEBS Lett 1996, 223: 284-8.
9. Arai, M., Lefer, D., So, T. et al. An anti-CD18 antibody limits infarct size and preserves left ventricular function in dogs with ischemia and 48-hour reperfusion. J Am Coll Cardiol 1996, 5: 1278-85.
10. Simpson, P., Todd, R., III, Fantone, J. et al. Sustained limitation of myocardial reperfusion injury by a monoclonal antibody (anti-Mo1, anti-CD11b) that inhibits leukocyte adhesion. J Clin Invest 1988, 2: 624-9.
11. Simpson, P., Todd, R., III, Mickelson, J. et al. Sustained limitation of myocardial reperfusion injury by a monoclonal antibody that alters leukocyte function. Circulation 1990, 1: 226-37.
12. Frangogiannis, N. and Entman, M. Mast cells in myocardial ischaemia and reperfusion. In: Mast cells and Basophils in Physiology, Pathology and Host Defense. G. Marone, L. Liechtenstein and S. Galli (Eds.). Academic Press, London 2000: 507-22.
13. Barone, F., Arvin, B., White, R. et al. Tumor necrosis factor-alpha. A mediator of focal ischemic brain injury. Stroke 2000, 28: 1233-44.
14. Rothwell, N., Allen, S. and Toulmond, S. The role of interleukinl in acute neurodegeneration and stroke: Pathophysiological and therapeutic implications. J Clin Invest 1997, 100: 2648-52.
15. Barone, F. and Feuerstein, G. Inflammatory mediators and stroke: New opportunities for novel therapeutics. J Cereb Blood Flow Metab 1999, 19: 819-34.
16. Relton, J. and Rothwell, N. Interleukin-I receptor antagonist inhibits ischaemic and excitotoxic neuronal damage in the rat. Brain Res Bull 1992, 29: 243-6.
17. Iadecola, C. and Ross, M. Molecular pathology of cerebral ischemia: Delayed gene expression and strategies for neuroprotection. Ann NY Acad Sci 1997, 835: 203-17.
18. Zhao, X., Haensel, C., Araki, E., Ross, M. and Iadecola, C. Gene-dosing effect and persistence of reduction in ischemic brain injury in mice lacking inducible nitric oxide synthase. Brain Res 2000, 872: 215-8.
19. Jugdutt, B. Nitric oxide and cardioprotection during ischemia- reperfusion. Heart Fail Rev 2002, 7: 391-405.
20. Finkel, M., Oddis, C., Jacob, T. et al. Inhibition of nitric oxide synthesis reduces infarct size by art adenosine-dependent mechanism. Science 1992, 257: 387-9.
21. Schulz, R., Panas, D., Catena, R. et al. The role of nitric oxide in cardiac depression induced by interleukin-1beta and tumour necrosis factor alpha. Br J Pharmacol 1995, 114: 27-34.
22. Wildhirt, S., Weismueller, S., Schulze, C., Conrad, N., Kornberg, A. and Reichart, B. Inducible nitric oxide synthase activation after ischemia/reperfusion contributes to myocardial dysfunction and extent of infarct size in rabbits: Evidence for a late phase of nitric oxide-mediated reperfusion injury. Cardiovasc Res 1999, 43: 698-711.
23. Saito, T., Rodger, I., Shennib, H., Hu, F., Tayara, L. and Giaid, A. Cyclooxygenase-2 (COX-2) in acute myocardial infarction: Cellular expression and use of selective COX-2 inhibitor. Can J Physiol Pharmacol 2003, 81: 114-9.
24. White, W., Faich, G., Borer, J. and Makuch, R. Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. Am J Cardiol 2003, 92: 411-8.
25. Ellison, I., Barone, F. and Feurstein, G. Matrix remolding after stroke. De novo expression of matrix proteins and integrin receptors. Ann NY Acad Sci 1999, 890: 204-22.
26. Hwang, M.-Y., Matsumori, A., Furukawa, Y. et al. Neutralization of interleukin-1beta in the acute phase of myocardial infarction promotes the progression of left ventricular remodeling. J Am Coll Cardiol 2001, 38: 1546-53.
27. Lemberger, T., Desvergne, B. and Wahli, W. The peroxisome proliferator-activated receptors: A nuclear receptor signaling pathway in lipid physiology. Annu Rev Cell Dev Biol 1996, 12: 335-63.
28. Desvergne, B. and Wahli, W. Peroxisome proliferator-activated receptors: Nuclear control of metabolism. Endocrine Rev 1999, 20: 649-88.
29. Olefsky, J. Treatment of insulin resistance with peroxisome proliferator-activated receptor-gamma agonists. J Clin Invest 2000, 106: 467-72.
30. Saltiel, A. and Olefsky, J. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996, 45: 1661-9.
31. Fujiwara, T., Okuno, A., Yoshioka, S. and Horikoshi, H. Suppression of hepatic gluconeogenesis in long term troglitazone treated diabetic KK and C57BL/LsJ-db mice. Metabolism 1995, 44: 486-90.
32. Stevenson, R., McPherson, R., Genereux, B., Danbury, B. and Kreutter, D. Antidiabetic agent englitazone enhances insulin action in nondiabetic rats without producing hypoglycemia. Metabolism 1991, 140: 1268-74.
33. Fonseca, V. Management of diabetes mellitus and insulin resistance in patients with cardiovascular disease. Am J Cardiol 2003, 92: 50-60J.
34. Tolman, K. and Chandramouli, J. Hepatotoxicity of the thiazolidinediones. Clin Liver Dis 2003, 7: 369-79.
35. Daynes, R. and Jones, D. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2002, 2: 748-59.
36. Alleve, D., Johnson, E., Lio, F., Boehme, S., Conlon, P. and Crowe, P. Regulation of marine macrophage proinflammatory and anti-inflammatory cytokines by ligands for peroxisome proliferator-activated receptor-gamma counter-regulatory activity by IFN-gamma. J Leukoc Biol 2002, 71: 677-85.
37. Clark, R., Bishop-Bailey, D., Estrada-Hernandez, T., Hla, T., Puddington, L. and Padula, S. The nuclear receptor PPARgamma and immunoregulation: PPARgamma mediates inhibition of helper T cell responses. J Immunol 2000, 164: 1364-71.
38. Gosset, P., Charbonnier, A., Delerive, P., Fontaine, J., Staels, B., Pestel, J. and Tonnel, A. Peroxisome proliferator-activated receptor-gamma activators affect the maturation of human monocyte-derived dendritic cells. Eur J Immunol 2001, 31: 2857-65.
39. Harris, S. and Phipps, R. The nuclear receptor PPARgamma is expressed by mouse T lymphocytes and PPARgamma agonists induce apoptosis. Eur J Immunol 2001, 31: 1098-105.
40. Padilla, J., Leung, E. and Phipps, R. Human B Lymphocytes and B lymphomas express PPARgamma and are killed by PPARgamma agonists. Clin Immunol 2002, 103: 22-33.
41. Setoguchi, K., Misaki, Y., Terauchi, Y., Yamauchi, T., Kawahata, K., Kadowaki, T. and Yamaoki, K. Peroxisome proliferator-activated receptor-gamma haploinsufficiency enhances B cell proliferative responses and exacerbates experimentally induced arthritis. J Clin Invest 2001, 108: 1667-75.
42. Huang, J., Welch, J., Ricote, M., Binder, C., Willson, T., Kelly, C., Witztum, J., Funk, C., Conrad, D. and Glass, C. Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature 1999, 400: 378-82.
43. Ricote, M., Li, A., Willson, T., Kelly, C. and Glass, C. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998, 391: 79-82.
44. Ricote, M., Huang, J., Fajas, L. et al. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA 1998, 95: 7614-9.
45. Kawahito, Y., Kondo, M., Tsubouchi, Y., Hashiramoto, A., Bishop-Bailey, D., Inoue, K., Kohno, M., Yamada, R., Hla, T. and Sano, H. 15-deoxy-DELTA12,14- PGJ2 induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J Clin Invest 2000, 106: 189-97.
46. Diab, A., Deng, C., Smith, J., Hussain, R., Phanavanh, B., Lovett-Racke, A., Drew, P. and Racke, M. Peroxisome proliferator-activated receptor-gamma-agonist 15-deoxy-DELTA12,14-prostaglandin J2 ameliorates experimental autoimmune encephalomyelitis. J Immunol 2002, 168: 2508-15.
47. Chinetti, G., Griglio, S., Antonucci, M., Pineda Torra, I., Delerive, P., Majd, Z., Fruchart, J.-C., Chapman, J., Najib, J. and Staels, B. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem 1998, 273: 25573-80.
48. Law, R., Goetze, S., Xi, X.-P., Jackson, S., Kawano, Y., Demer, L., Fishbein, M., Meehan, W. and Hsueh, W. Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation 2002, 101: 1311-8.
49. Diep, Q. and Schiffrin, E. Increased expression of peroxisome proliferator-activated receptor-alpha and -gamma in blood vessels of spontaneously hypertensive rats. Hypertension 2001, 38: 249-54.
50. Chen, N. and Han, X. Dualfunction of troglitazone in ICAM-I gene expression in human vascular endothelium. Biochem Biophys Res Com 2001, 282: 717-22.
51. Pasceri, V., Wu, H., Willerson, J. and Yeh, E. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 2000, 101: 235-8.
52. Jiang, C., Ting, A. and Seed, B. PPAR-gamma agonist inhibits production of inflammatory cytokines. Nature 1998, 391: 82-6.
53. Heneka, M., Feinstein, D., Galea, E., Gleichmann, M., Wullner, U. and Klockgether, T. Peroxisome proliferator-activated receptor gamma agonists protect cerebellar granular cells from cytokine-induced apoptotic cell death by inhibition of inducible nitric oxide synthase. J Neuroimmunol 1999, 100: 156-68.
54. Heneka, M., Klockgether, T. and Feinstein, D. Peroxisome proliferator-activated re-ceptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J Neurosci 2000, 20: 6862-7.
55. Kitamura, Y., Kakimura, J., Matsuoka, Y., Nomura, Y., Gebicke-Haerter, P. and Taniguchi, T. Activators of peroxisome proliferator-activated receptor-gamma (PPARgamma) inhibit inducible nitric oxide synthase expression but increase heme oxygenase-1 expression in rat glial cells. Neurosci Lett 1999, 262: 129-32.
56. Subbaramaiah, K., Lin, D., Hart, J. and Dannenberg, A. Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2. J Biol Chem 2001, 276: 12440-8.
57. Marx, N., Sukhova, G., Murphy, C., Libby, P. and Plutzky, J. Macrophages in human atheroma contain PPARgamma: Differentiation-dependent peroxisomal proliferator-activated receptor-gamma (PPAR-gamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol 1998, 153: 17-23.
58. Shu, H., Wong, B., Zhou, G. et al. Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells. Biochem Biophys Res Com 2000, 267: 345-9.
59. Kintscher, U., Goetze, S., Wakino, S. et al. Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes. Eur J Pharmacol 2000, 401: 259-70.
60. Chawla, A., Boisvert, W., Lee, C.-H. et al. A PPARgamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 2001, 7: 161-71.
61. Joseph, S., Castrillo, A., Laffitte, B., Mangelsdorf, D. and Tontonoz, P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 2003, 9: 213-9.
62. Yang, X., Wang, L., Mihalic, K. et al. Interleukin (IL)-4 indirectly suppresses IL-2 production by human T lymphocytes via peroxisome proliferator-activated re-ceptor gamma activated by macrophage-derived 12/15 lipoxygenase ligands. J Biol Chem 2002, 277: 3973-8.
63. Castrillo, A., Diaz-Guerra, M., Hortelano, S., Martin-Sanz, P. and Bosca, L. Inhibition of IkappaB kinase and IkappaB phosphorylation by 15-deoxy-DELTA12,14-prostaglandin J2 in activated murine macrophages. Mol Cell Biol 2000, 20: 1692-8.
64. Straus, D., Pascual, G., Li, M., Welch, J., Ricote, M., Hsiang, C.-H., Sengchanthalangsy, L., Gosh, G. and Glass, C. 15-deoxy-DELTA12,14-prostaglandin J2 inhibits multiple steps in the NF-kappaB signaling pathway. Proc Natl Acad Sci USA 2000, 97: 4844-9.
65. Chawla, A., Barak, Y., Nagy, L., Lioa, D., Tontonoz, P. and Evans, M. PPAR-gamma dependent and independent effects on macrophage gene expression in lipid metabolism and inflammation. Nat Med 2001, 7: 48-52.
66. Moore, K., Rosen, E., Fitzgerald, M. et al. The role of PPARgamma in macrophage differentiation and cholesterol uptake. Nat Med 2000, 7: 41-7.
67. Li, M., Pascual, G. and Glass, C. Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene. Mol Cell Biol 2000, 20: 4699-707.
68. Welch, J., Ricote, M., Akiyama, T., Gonzalez, F. and Glass, C. PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc Natl Acad Sci USA 2003, 100: 6712-7.
69. Marx, N., Schonbeck, U., Lazar, M., Libby, P. and Plutzky, J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 1998, 83: 1097-103.
70. Staels, B., Koenig, W., Habib, A. et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not PPARgamma activators. Nature 1998, 393: 790-3.
71. Duval, C., Chinetti, G., Trottein, F., Cruchart, J.-C. and Staels, B. The role of PPARs in atherosclerosis. Trends Mol Med 2003, 8: 422-30.
72. Murao, K., Imachi, H., Momoi, A. et al. Thiazolidinediones inhibit the production of monocyte chemoattractant protein-1 in cytokine-treated human vascular endothelial cells. FEBS Lett 1999, 454: 27-30.
73. Lee, H., Shi, W., Tontonoz, P. et al. Role of peroxisome proliferator-activated receptor alpha in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells. Circ Res 2000, 87: 516-21.
74. Han, K. and Quehenberger, O. Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated gamma. J Clin Invest 2000, 106: 793-802.
75. Collins, A., Meehan, W., Kintscher, U. et al. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2001, 21: 365-71.
76. Koshiyama, H., Shimono, D., Kuwamura, N., Minamikawa, J. and Nakamura, Y. Rapid communication: Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001, 86: 3452.
77. Mizushige, K., Noma, T., Yao, L. et al. Effects of troglitazone on collagen accumulation and distensibility of aortic wall in prestage of non-insulin-dependent diabetes mellitus of Otsuka Long-Evans Tokushima fatty rats. J Cardiovasc Pharmacol 2000, 35: 150-5.
78. Aizawa, Y., Kawabe, J., Hasebe, N., Takehara, N. and Kikuchi, K. Pioglitazone enhances cytokine-induced apoptosis in vascular smooth muscle cells and reduced intimal hyperplasia. Circulation 2001, 97: 2307-15.
79. Wanderi, E., Gamboa, J., Victor, N., Landreth, G., Lust, W. and Sundararajan, S. Expression of the transcription factor, peroxisome proliferator-activated receptor-gamma is increased in ischemic rat brain. Soc for Neurosci Meet (Nov 2-7, Orlando) 2002, Abst 694.13.
80. Aronowski, J. Peroxisome proliferator-activated receptor reduces damage produced by focal ischemia. Soc for Neurosci Meet (Nov 2-7, Orlando) 2002, Abst 389.6.
81. Sundararajan, S., Lust, W., Landis, D. and Landreth, G. PPARgamma agonists reduce ischemic injury and immunoreactivity against inflammatory markers in rats. Soc for Neurosci Meet (Nov 4-9, New Orleans) 2000, Abst 670.8.
82. Sundararajan, S., Wanderi, E., Lust, W. and Landreth, G. A PPARgamma agonist reduces infarct volume and improves functional outcome following focal ischemia. Soc for Neurosci Meet (Nov 10-15, San Diego) 2001, Abst 864.4.
83. Gamboa, J., Victor, N., Landreth, G. and Sundararajan, S. Pioglitazone, a PPARgamma agonist, reduces infarct size and improves neurologic function in transient focal ischemia. Soc Neurosci Meet (Nov 8-12, New Orleans) 2003, Abst 102.17.
84. Shimazu, T. and Greenberg, J. A PPARgamma agonist reduces infarct size in transient but not permanent ischemia. Soc Neurosci Meet (Nov 8-12, New Orleans) 2003, Abst 883.4.
85. Deplanque, D., Gele, P., Petrault, O. et al. Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci 2003, 23: 6264-71.
86. Marx, N., Sukhova, G., Collins, T., Libby, P. and Plutzky, J. PPARalpha activators inhibit cytokine-induced vascular cell ad-hesion molecule-1 expression in human endothelial cells. Circulation 1999, 99: 3125-31.
87. Wayman, N., Hattori, Y., McDonald, M. et al. Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J 2002, 16: 1027-40.
88. Breidert, T., Callebert, J., Heneka, M., Landreth, G., Launay, J. and Hirsch, E. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem 2002, 82: 615-24.
89. Niino, M., Iwabuchi, K., Kikuchi, S. et al. Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-acti-vated receptor-gamma. J Neuroimmunol 2001, 116: 40-8.
90. Feinstein, D., Galea, E., Gavrilyuk, V. et al. Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann Neurol 2002, 51: 694-702.
91. Combs, C., Johnson, D., Karlo, C., Cannady, S. and Landreth, G. Inflammato-ry mechanisms in Alzheimer's disease: Inhibition of beta-amyloid stimulated pro-inflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci 2000, 20: 558-67.
92. Uryu, S., Harada, J., Hisamoto, M. and Oda, T. Troglitazone inhibits both post-glutamate neurotoxicity and low potassium-induced apoptosis in cerebellar granule neurons. Brain Res 2002, 924: 229-36.
93. Aoun, P., Watson, D. and Simpkins, J. Neuroprotective effects of PPARgamma agonist against oxidative insults in HT-22 cells. Eur J Pharmacol 2003, 472: 65-71.
94. Yue, T., Chen, J., Bao, W. et al. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation 2002, 104: 2588-94.
95. Shiomi, T., Tsutsui, H., Hayashidani, S. et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002, 106: 3126-32.